The global cell surface marker detection market size was estimated to be USD 5.76 billion in 2023 and is expected to reach USD 14.02 billion by 2034 with a CAGR of 8.43% during the forecast period 2024-2034. The market will rise as a result of factors such as rising demand for personalized medicine, growing research and development activities, rising prevalence of cancer and other diseases, and strategic collaborations and partnerships.
The increasing prevalence of cancer and autoimmune diseases has created a heightened demand for precise diagnostic tools, such as cell surface marker detection, which are essential for identifying specific cell types and monitoring disease progression. According to the American Cancer Society (ACS), cancer remains the second leading cause of death in the United States, following heart disease. In 2023, the ACS anticipates that there will be approximately 1.9 million new cancer cases, which translates to about 5,370 new cases each day. Furthermore, it is projected that 609,820 individuals will succumb to cancer this year, equating to roughly 1,670 deaths per day in the U.S. These statistics underscore the urgent need for advanced diagnostic methodologies to improve patient outcomes in the face of rising cancer rates.
By product, the reagents & kits segment accounted for the highest revenue-grossing segment in the global cell surface marker detection market in 2023 owing to the growing demand for advanced diagnostic tools and research applications, as well as the continuous development of innovative reagents and kits that enhance the accuracy and efficiency of cell surface marker detection. For instance, Zoetis Inc., launch its new hematology analyzer, Vetscan OptiCellTM, in September 2024. This diagnostic equipment uses artificial intelligence (AI) and is cartridge-based, providing advanced Complete Blood Count (CBC) analysis. The analyzer, which will be available in the US later this year, is a major technological advancement that will help veterinary care teams save a substantial amount of time, money, and space while also improving patient outcomes and clinic workflow. Additionally, the hematology analyzers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased demand for precise blood diagnostics, advancements in technology that improve analyzer efficiency, and the rising prevalence of blood disorders requiring rapid and accurate analysis.
By application, the disease diagnosis & identification segment accounted for the highest revenue-grossing segment in the global cell surface marker detection market in 2023 owing to the growing need for accurate and early disease diagnosis, particularly in cancer and autoimmune diseases, which drives the demand for reliable cell surface marker detection technologies. For instance, in May 2024, Bio-Rad's StarBright Dyes were widely used in flow cytometry because of their simplicity of introduction into pre-existing panels, brightness, stability, and narrow excitation and emission properties. When building conventional and full-spectrum multicolor flow cytometry panels, Bio-Rad gives researchers even more options and flexibility with its ongoing growth of the StarBright Dye range. Additionally, the research & drug discovery segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on personalized medicine, advancements in biomedical research, and the rising need for efficient drug development processes that rely on precise identification of cell surface markers.
By end-user, the pharmaceutical & biotechnology companies segment accounted for the highest revenue-grossing segment in the global cell surface marker detection market in 2023 owing to the significant investments in research and development, the need for innovative diagnostic tools, and the growing emphasis on targeted therapies that rely on accurate cell surface marker identification. For instance, the European laboratory equipment provider Diatron debuted Aquarius 3, the newest in vitro diagnostic (IVD) hematology analyzer intended for Complete Blood Count testing, in January 2023. The Aquarius 3 introduces a new series of hematology analyzers that expands on the strong counting capabilities of Diatron's flagship model, the Abacus 380. To the advantage of both consumers and businesses, it does, however, offer additional features that improve operability and connectivity and allow adaption to a variety of contexts. Additionally, the research institutes segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased funding for biomedical research, rising collaboration between academic and industry partners, and the growing demand for advanced techniques in cell biology and disease studies.
North American region is anticipated for the highest revenue share during the forecast period owing to the presence of leading pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and significant investments in research and development activities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing research activities, and rising investments in biotechnology and pharmaceuticals in emerging markets. For instance, the Japanese healthcare company Sysmex Corporation introduced its Clinical Flow Cytometry System in May 2023. The Flow Cytometer XF-1600, the Sample Preparation System PS-10, antibody reagents, and other relevant goods are all integrated into this all-inclusive system. The system improves efficiency and standardization in laboratories by providing a fully automated testing procedure for clinical Ferric carboxymaltose (FCM) testing, from sample preparation to measurement results reporting. Clinical technologists' workload is lessened by this automation, freeing them up to focus on the more technically complex examination of test results.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The increasing prevalence of cancer and autoimmune diseases has created a heightened demand for precise diagnostic tools, such as cell surface marker detection, which are essential for identifying specific cell types and monitoring disease progression. According to the American Cancer Society (ACS), cancer remains the second leading cause of death in the United States, following heart disease. In 2023, the ACS anticipates that there will be approximately 1.9 million new cancer cases, which translates to about 5,370 new cases each day. Furthermore, it is projected that 609,820 individuals will succumb to cancer this year, equating to roughly 1,670 deaths per day in the U.S. These statistics underscore the urgent need for advanced diagnostic methodologies to improve patient outcomes in the face of rising cancer rates.
By product, the reagents & kits segment accounted for the highest revenue-grossing segment in the global cell surface marker detection market in 2023 owing to the growing demand for advanced diagnostic tools and research applications, as well as the continuous development of innovative reagents and kits that enhance the accuracy and efficiency of cell surface marker detection. For instance, Zoetis Inc., launch its new hematology analyzer, Vetscan OptiCellTM, in September 2024. This diagnostic equipment uses artificial intelligence (AI) and is cartridge-based, providing advanced Complete Blood Count (CBC) analysis. The analyzer, which will be available in the US later this year, is a major technological advancement that will help veterinary care teams save a substantial amount of time, money, and space while also improving patient outcomes and clinic workflow. Additionally, the hematology analyzers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased demand for precise blood diagnostics, advancements in technology that improve analyzer efficiency, and the rising prevalence of blood disorders requiring rapid and accurate analysis.
By application, the disease diagnosis & identification segment accounted for the highest revenue-grossing segment in the global cell surface marker detection market in 2023 owing to the growing need for accurate and early disease diagnosis, particularly in cancer and autoimmune diseases, which drives the demand for reliable cell surface marker detection technologies. For instance, in May 2024, Bio-Rad's StarBright Dyes were widely used in flow cytometry because of their simplicity of introduction into pre-existing panels, brightness, stability, and narrow excitation and emission properties. When building conventional and full-spectrum multicolor flow cytometry panels, Bio-Rad gives researchers even more options and flexibility with its ongoing growth of the StarBright Dye range. Additionally, the research & drug discovery segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on personalized medicine, advancements in biomedical research, and the rising need for efficient drug development processes that rely on precise identification of cell surface markers.
By end-user, the pharmaceutical & biotechnology companies segment accounted for the highest revenue-grossing segment in the global cell surface marker detection market in 2023 owing to the significant investments in research and development, the need for innovative diagnostic tools, and the growing emphasis on targeted therapies that rely on accurate cell surface marker identification. For instance, the European laboratory equipment provider Diatron debuted Aquarius 3, the newest in vitro diagnostic (IVD) hematology analyzer intended for Complete Blood Count testing, in January 2023. The Aquarius 3 introduces a new series of hematology analyzers that expands on the strong counting capabilities of Diatron's flagship model, the Abacus 380. To the advantage of both consumers and businesses, it does, however, offer additional features that improve operability and connectivity and allow adaption to a variety of contexts. Additionally, the research institutes segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased funding for biomedical research, rising collaboration between academic and industry partners, and the growing demand for advanced techniques in cell biology and disease studies.
North American region is anticipated for the highest revenue share during the forecast period owing to the presence of leading pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and significant investments in research and development activities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing research activities, and rising investments in biotechnology and pharmaceuticals in emerging markets. For instance, the Japanese healthcare company Sysmex Corporation introduced its Clinical Flow Cytometry System in May 2023. The Flow Cytometer XF-1600, the Sample Preparation System PS-10, antibody reagents, and other relevant goods are all integrated into this all-inclusive system. The system improves efficiency and standardization in laboratories by providing a fully automated testing procedure for clinical Ferric carboxymaltose (FCM) testing, from sample preparation to measurement results reporting. Clinical technologists' workload is lessened by this automation, freeing them up to focus on the more technically complex examination of test results.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Cell Surface Marker Detection Market Report 2023 - 2034
Cell Surface Marker Detection Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Flow Cytometry
- Hematology Analyzers
- Reagents & Kits
Cell Surface Marker Detection Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Disease Diagnosis & Identification
- Research & Drug Discovery
- Others
Cell Surface Marker Detection Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Cell Surface Marker Detection Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cell Surface Marker Detection Market: Product Estimates & Trend Analysis
8. Cell Surface Marker Detection Market: Application Estimates & Trend Analysis
9. Cell Surface Marker Detection Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Cell Surface Marker Detection Market
12. Europe Global Cell Surface Marker Detection Market
13. Asia Pacific Global Cell Surface Marker Detection Market
14. Latin America Global Cell Surface Marker Detection Market
15. MEA Global Cell Surface Marker Detection Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- BD Biosciences
- Beckman Coulter (a subsidiary of Danaher Corporation)
- Thermo Fisher Scientific
- Merck KGaA (MilliporeSigma in the U.S.)
- Bio-Rad Laboratories
- Abbott Laboratories
- Glycotope GmbH
- R&D Systems (a part of Bio-Techne Corporation)
- Luminex Corporation
- Miltenyi Biotec
- Agenus Inc.
- Stemcell Technologies
- Illumina Inc.
- Qiagen N.V.
- CureVac AG.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 5.76 Billion |
| Forecasted Market Value ( USD | $ 14.02 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
